FDA Seeks Patient Input on Nonhealing Chronic Wounds

On August 25, the Food and Drug Administration (FDA) will host a Patient-Focused Drug Development meeting on nonhealing chronic wounds. APMA encourages members to share this opportunity with patients and caregivers who may be interested in participating.

The purpose of the meeting is to help FDA and other stakeholders better understand the patient experience, including how chronic wounds affect daily life, challenges with current treatments, and factors that influence participation in clinical trials. Discussions will focus on health and quality-of-life impacts, current treatment approaches, and patient perspectives on clinical research.

FDA is seeking a diverse group of patients and care partners representing different wound types and treatment experiences. Participation options include serving on a patient panel, contributing during discussion sessions, submitting comments electronically, or attending as an observer.

The meeting will be held in a hybrid format, allowing participation either virtually or in person. Additional information and registration details are available on the FDA's website. Deadline for registration is August 23.